| Date | Title | Description |
| 02.08.2021 | Precigen : to Announce Second Quarter and First Half 2021 Financial Results on August 9th | GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company wil... |
| 02.08.2021 | Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th | |
| 10.06.2021 | Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes | |
| 30.03.2021 | Precigen Announces Departure of Chief Financial Officer | |
| 30.03.2021 | PRECIGEN, INC.
Precigen : Announces Departure of Chief Financial Officer | GERMANTOWN, Md., March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Ric... |
| 23.03.2021 | Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) | |
| 18.03.2021 | Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) | |
| 01.03.2021 | Precigen Reports Fourth Quarter and Full Year 2020 Financial Results | |
| 22.02.2021 | Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st | |
| 26.01.2021 | Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares | |
| 22.01.2021 | Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock | |
| 21.01.2021 | Precigen Announces Proposed Public Offering of Common Stock | |
| 12.01.2021 | Next Green Wave : Announces Q4 Results and Corporate Appointments | Vancouver, B.C. - Jan 12, 2021 - Next Green Wave Holdings Inc. (CSE: NGW) (OTCQX: NXGWF) ('Next Green Wave', 'NGW' or the 'Company') is pleased to announce the following corporate and financial updates:
The Company would like to highlight s... |
| 05.01.2021 | Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) | |
| 16.11.2020 | Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials | |
| 15.10.2020 | Precigen's UltraPorator™ Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials | |
| 27.09.2019 | How To Spot A Synthetic Biology Unicorn | Biotech is projected to reach $775 billion by 2024, but dozens of companies in the field of ... [+] synthetic biology are creating magical tools to go beyond that. Look here for the next unicorn. Jelena Trmčić for SynBioBeta |
